Author:
Slingluff Craig L.,Petroni Gina R.,Olson Walter C.,Smolkin Mark E.,Chianese-Bullock Kimberly A.,Mauldin Ileana S.,Smith Kelly T.,Deacon Donna H.,Varhegyi Nikole E.,Donnelly Sean B.,Reed Caroline M.,Scott Kristy,Galeassi Nadejda V.,Grosh William W.
Funder
GlaxoSmithKline
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Immunology,Immunology and Allergy
Reference44 articles.
1. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105(5):1650–1655
2. Burny W, Dantinne C, Amrani N, Vantomme V, Coulie P, Brichard V, Van Mechelen M (2006) Measurement of the specific T cell response in melanoma patients immunized with a recombinant MAGE-A3 immunotherapeutic: development of a sensitive read-out for serial monitoring. J Immunother 29(6):659–660 (Abstract)
3. Pellegrino P, Clementi E, Radice S (2015) On vaccine’s adjuvants and autoimmunity: current evidence and future perspectives. Autoimmun Rev 14(10):880–888
4. Olafsdottir T, Lindqvist M, Harandi AM (2015) Molecular signatures of vaccine adjuvants. Vaccine. doi:
10.1016/j.vaccine.2015.04.099
5. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31(19):2413–2420
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献